Aminotelopeptide in Urine: Measurement and Application Opportunities in Diagnostics of Metastatic Bone Disease
Dalius Vitkus, Aušrytė Kaminskienė
Summary
Objective. To assess the value of urine aminotelopeptide determination using enzyme-linked immunoassay in diagnosis of metastatic bone disease and as indicator for determining relative risk of metastatic bone disease.
The article presents original data from Vilnius University Hospital Santa- riskiu Clinics collected during period of 2010-2012. Patients with prostate, breast tumor or multiple myeloma were selected for the study.
Enzyme-linked immunoassay for determination of aminotelopeptide (NTX) was introduced at the laboratory using the commercial reagent kit (Ostex International, Seattle, USA) and an automated analyzer Gemini (Stratec). It was found that 56 out of 83 patients had increased levels of aminotelopeptide in urine. 31 of 56 patients were suspected to have metastatic bone disease if amino- telopeptide concentration 3 or more times higher than the recommended value. The relative risk of metastatic bone disease in patients with NTX levels > 168 nmol BCE / mmol creatinine increases 3.06 times. Normal ranges of urine aminotelopeptide in group of healthy adults based on local population were determined: 22-56 nmol BCE / mmol creatinine.
Keywords: bone resorbtion markers, aminotelopeptide, metastatic bone disease, bone remodeling.